Market closed
Iovance Biotherapeutics/$IOVA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
557
Website
IOVA Metrics
BasicAdvanced
$1.6B
-
-$1.48
0.53
-
Price and volume
Market cap
$1.6B
Beta
0.53
52-week high
$18.33
52-week low
$5.05
Average daily volume
8M
Financial strength
Current ratio
4.223
Quick ratio
3.839
Long term debt to equity
8.713
Total debt to equity
10.206
Management effectiveness
Return on assets (TTM)
-29.15%
Return on equity (TTM)
-56.65%
Valuation
Price to revenue (TTM)
16.35
Price to book
2.11
Price to tangible book (TTM)
3.49
Price to free cash flow (TTM)
-3.971
Growth
Revenue change (TTM)
12,751.20%
Earnings per share change (TTM)
-27.65%
3-year earnings per share growth (CAGR)
-10.59%
What the Analysts think about IOVA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
IOVA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IOVA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IOVA News
AllArticlesVideos
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 hours ago
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
GlobeNewsWire·7 hours ago
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $1.6B as of February 28, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of February 28, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of February 28, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.